Home
About
Overview
Sharing Data
ORCID
Help
History (38)
Single-institution experience with pemetrexed and bevacizumab as salvage therapy in advanced non-small-cell lung cancer.
Obesity and its association to phenotype and clinical course in hypertrophic cardiomyopathy.
Inhibition of dendritic spine morphogenesis and synaptic transmission by activity-inducible protein Homer1a.
Reviewing concomitant medications for participants in oncology clinical trials.
Tailoring tyrosine kinase inhibitors to fit the lung cancer genome.
See All 38 Pages
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Tailoring tyrosine kinase inhibitors to fit the lung cancer genome.
Looyenga BD, Cherni I, Mackeigan JP, Weiss GJ. Tailoring tyrosine kinase inhibitors to fit the lung cancer genome. Transl Oncol. 2011 Apr 01; 4(2):59-70.
View in:
PubMed
authors with profiles
Glen Weiss MD, MBA